Amino Science Labs sells research peptides exclusively to qualified researchers and laboratories for in vitro and laboratory use. Please confirm before continuing.
By proceeding you affirm the statements above are true. Products are not for human or veterinary use, not for use in diagnostic procedures, and have not been evaluated by the U.S. Food and Drug Administration. Full disclaimer.
🔥 FREE SHIPPING ON ORDERS OVER $250 🔥
Research Peptide
CJC-1295 with DAC for research.
Fast shipping
Same-day dispatch
Third-party tested
U.S. accredited labs
99%+ purity
HPLC verified
30AA
SEQUENCE + DAC
GHRH analogue with Drug Affinity Complex
8+days
HALF-LIFE
Extended via DAC albumin binding
2-10x
IGF-1 INCREASE
Sustained elevation in studies
30+
PUBLICATIONS
DAC-conjugated variant studies
3648Da
MOL. WEIGHT
With DAC modification
Free shipping
on orders over $150
Quality guarantee
99%+ purity verified
Secure checkout
256-bit SSL encryption
Research
This listing supplies CJC-1295 with DAC (2 mg) as a lyophilized reference peptide for in-vitro and preclinical laboratory work. CJC-1295 is a synthetic analog of the first 29 residues of growth-hormone-releasing hormone — the GRF(1-29) fragment — carrying a small set of amino-acid substitutions that improve resistance to enzymatic cleavage. The defining structural feature of this version is the DAC group: a Drug Affinity Complex built from a maleimidopropionyl lysine linker. That reactive tether is designed to form a covalent bond with a free cysteine thiol on circulating serum albumin, so in a research setting the peptide is studied as an albumin-binding, long-acting GRF analog rather than as a short-lived free peptide. The molecular formula for this product is C165H269N47O46, and it is registered under CAS 863288-34-0.
The distinction between the DAC and non-DAC forms matters when planning bench work. Without the DAC linker, modified GRF(1-29) (sometimes catalogued as CJC-1295 'no-DAC' or Mod-GRF 1-29) behaves as a comparatively short-lived analog; the DAC modification is what confers the extended albumin-association profile that researchers characterize in this material. All descriptions below concern the research substance itself — its documented study history and its analytical fingerprint — and make no claim about outcomes in humans or animals.
Published investigations of CJC-1295 with DAC are laboratory and preclinical in nature. As a GHRH-receptor-directed analog, it has been used in cell-based receptor-binding and signaling assays that probe the class B G-protein-coupled GHRH receptor and downstream cAMP responses in cultured pituitary-derived cells. The albumin-affinity behavior conferred by the maleimide-DAC chemistry has itself been a subject of characterization work, since the thiol-maleimide conjugation is the mechanistic basis for the compound's extended plasma-association profile observed in animal models.
Research context only
These references describe experimental laboratory work. They are not medical claims, are not evidence of safety or efficacy in humans or animals, and should not be read as guidance for any use outside a controlled research environment. The science surrounding this compound remains preliminary and ongoing, and nothing here constitutes medical advice.
Each research lot is supplied as a lyophilized powder and characterized before release so the material matches the sequence and mass expected for the DAC-modified GRF(1-29) analog. Identity and purity are established with orthogonal methods, keeping the two questions separate: purity asks how much of the sample is the target peptide, while identity confirms the target is the correct molecule with the maleimide-lysine linker intact.
The Certificate of Analysis (COA) accompanying each product is the definitive analytical record for that specific lot. Because purity and mass can vary slightly between synthesis batches, researchers should reference the COA tied to the lot number received rather than generic specifications when documenting experimental inputs. Because the maleimide moiety in the DAC linker is thiol-reactive, standard laboratory handling calls for reconstitution with a thiol-free research-grade solvent, keeping the sealed vial equilibrated to room temperature before opening to limit condensation on the hygroscopic solid, and aliquoting the stock to minimize freeze-thaw cycles. Detailed temperature and stability windows appear in the storage table on this page.
DAC stands for Drug Affinity Complex — a maleimidopropionyl lysine linker attached to the modified GRF(1-29) peptide. In a research setting this reactive group is characterized for its ability to form a covalent thiol-maleimide bond with a free cysteine on serum albumin, which is the mechanistic basis for the compound's albumin-associated, long-acting profile in preclinical models. It is the feature that distinguishes this material from the non-DAC (modified GRF 1-29) analog.
Both are analogs of the GRF(1-29) fragment of GHRH with substitutions that improve enzymatic stability. The difference is the DAC linker: the no-DAC form lacks the maleimide-lysine tether and is studied as a comparatively short-lived analog, whereas this DAC version is characterized for its extended albumin-association behavior. Researchers choose between them based on the clearance and receptor-exposure profile relevant to their in-vitro or preclinical design.
It ships as a lyophilized (freeze-dried) powder in a sealed vial at a 2 mg peptide mass. Lyophilization improves shelf stability, and the researcher reconstitutes it using standard aseptic laboratory technique when preparing in-vitro experiments. Because the DAC linker contains a thiol-reactive maleimide, a thiol-free research-grade solvent is typically used for reconstitution.
Purity is measured by reversed-phase HPLC and reported as a percentage of total peak area (≥98% for this product), while identity is confirmed by mass spectrometry against the theoretical mass for the C165H269N47O46 sequence. The lot-specific COA documents both values plus appearance and net peptide content, and is the authoritative analytical record for the exact material you receive.
This product is sold strictly for in-vitro research and laboratory use only. It is not intended for human or animal consumption, diagnostic purposes, or therapeutic application.
By purchasing this product, you confirm that you are a qualified researcher operating within an appropriate laboratory environment and will use this compound in accordance with all applicable local, state, and federal regulations.
Amino Science Labs assumes no liability for misuse of this product outside of its intended research application.
Published work is laboratory and preclinical, spanning in-vitro GHRH-receptor binding and cAMP-signaling assays in pituitary-derived cell lines, characterization of the maleimide-thiol albumin conjugation as a plasma-association strategy, and rodent-model pharmacokinetic comparisons between DAC and non-DAC GRF analogs. This research is preliminary and ongoing, describes laboratory systems only, and does not establish any human or animal outcome.
No. This material is supplied strictly for in-vitro and laboratory research use by qualified researchers. It is not a drug, supplement, or food, is not intended for human or animal consumption or any diagnostic or therapeutic purpose, and nothing on this page constitutes medical advice.
